Biocept Names Michael Dugan, M.D. Chief Medical Officer and Medical Director
“Mike is highly respected in the molecular diagnostics industry, and we are thrilled to welcome him to our executive team,” said
“I’m excited to join
About Biocept
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the outcomes of patients diagnosed with cancer, our ability to benefit from the addition of
Investor Contact:
LHA Investor Relations
Jcain@lhai.com
310-691-7100
Source: Biocept, Inc.